Penumbra’s Thunderbolt CAVT Platform Cleared by FDA for Stroke Treatment

June 11, 2026—Penumbra, Inc. announced it has received FDA clearance for the Thunderbolt computer-assisted vacuum thrombectomy (CAVT) platform for the treatment of acute ischemic stroke.

Powered by the Penumbra Engine, Thunderbolt introduces modulated aspiration to the company’s neuro thrombectomy portfolio, offering CAVT technology to detect, fatigue, and completely ingest clot at the site of the occlusion, stated Penumbra.

Thunderbolt will be prepackaged with one of Penumbra’s catheters: Red 62, Red 68, Red 72 Silver Label, or Red 72 Silver Label with SendIt technology, advised the company.

Donald Frei, MD, and David Fiorella, MD, discussed Thunderbolt in the company’s press release. Dr. Frei and Dr. Fiorella are Principal Investigators of the THUNDER trial, which is evaluating the safety and efficacy of the Penumbra Thunderbolt platform in a population presenting with acute ischemic stroke secondary to intracranial large vessel occlusion who are eligible for mechanical thrombectomy.

“Stroke is the second leading cause of death worldwide and with stroke, timing is critical. If the blood clot isn’t removed and the artery reopened quickly, patients can face severe disability or even death,” stated Dr. Frei, who is a neurointerventional radiologist at Swedish Medical Center in Denver, Colorado. “What sets Thunderbolt apart is the innovative design which minimizes catheter manipulation and promotes safe, complete clot capture—quickly restoring blood flow to the brain and giving patients the best chance at recovery.”

Dr. Fiorella added, “Modulated aspiration may facilitate more consistent and complete clot removal when used in conjunction with standard aspiration thrombectomy catheters. Our early experience with Thunderbolt within the context of the trial suggests that this technology will meaningfully change how we approach stroke treatment and could substantively improve outcomes in patients with emergent large vessel occlusion.” Dr. Fiorella is director of the Cerebrovascular Center at Stony Brook University Hospital in Stony Brook, New York.